Image

Global Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Lung Cancer Diagnostics Market, By Test Type (CA Test, HER2 Tests, ALK Tests, Angiogenesis Inhibitor, KRAS Mutation Tests, Others), Indication (Non Small-cell Lung Cancer, Small-cell Lung Cancer), End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others) – Industry Trends and Forecast to 2029.

Lung Cancer Diagnostics Market

Global Lung Cancer Diagnostics Market Analysis and Size

Cancer refers to a disease of genes that are caused due to abnormal growth of cells. Through blood and lymph system these abnormal cells further migrate from the original site to other site. Lung cancer is type of cancer that is formed in tissues of the lungs.

  • Diagnostic procedures for cancer consists of tumor biopsy, endoscopic examination, genetic testing, imaging, or surgery. Global lung cancer diagnostics market was valued at USD 181,750.84 million in 2021 and is expected to reach USD 331,456.49 million by 2029, registering a CAGR of 7.80% during the forecast period of 2022-2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Lung Cancer Diagnostics Market Definition

Cancer diagnostics refer to a method of identifying different proteins, biomarkers, and some signs that supports the identification of the presence of a cancerous tumor. Efficient diagnostic testing is utilized for ruling out the existence of illness, schedule and review treatment outcomes, and monitor the progression of the disease.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Test Type (CA Test, HER2 Tests, ALK Tests, Angiogenesis Inhibitor, KRAS Mutation Tests, Others), Indication (Non Small-cell Lung Cancer, Small-cell Lung Cancer), End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

H-Hoffman La-Rcohe Ltd. (Switzerland), ABBOTT (US), Danaher (US), BD (US), Thermo Fisher Scientific Inc. (US), ACON Laboratories Inc. (US), Hemosure, Inc. (US), MicroGen Diagnostics (US), QIAGEN (Germany), Grifols, S.A (Spain), BODITECH MED INC. (South Korea), Chembio Diagnostic Systems, Inc. (US), Nanoentek (South Korea), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), BIOMEDOMICS INC (US),  EKF Diagnostics Holdings plc (UK), Siemens Healthcare GmbH (Germany), PerkinElmer Inc. (US), bioMérieux SA (France), ARKRAY USA, Inc. (US), Biohit Oyj (Finland), Germaine Laboratories, Inc. (US), Quidel Corporation (US), Illumina, Inc. (US), Lamdagen Corporation (US), LifeSign LLC. (US), Medixbiochemica (Finaland), Nova Biomedical (US), Ortho Clinical Diagnostics (US), Sannuo Biosensing Co., Ltd. (US), STRECK (US), Sysmex Corporation (Japan), among others

Market Opportunities

  • Rise in the adoption of the unhealthy lifestyles
  • Rise in emphasis over health and safety regulations
  • Surge in technological advancements

Lung Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints and challenges. All of this is discussed in detail as below:

Drivers

  • Prevalence of Unhealthy Lifestyles

The rise in the adoption of the unhealthy lifestyles, such as smoking acts as one of the major factors driving the growth of lung cancer diagnostics market. Cigarette smoking is known to be prominent cause of lung cancer.

  • Technological Advancements

The surge in technological advancements result in better imaging of cancerous cells, increase in efficiency of the result and improvement in equipment to identify the type of cancer that further accelerate the market growth.

  • Government Initiatives

The increase in the government initiatives and other private organizations for spreading spread awareness regarding early diagnosis and prevention of cancer further influence the market.

Opportunities

Furthermore, rise in emphasis over health and safety regulations extend profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, growth in the number of diagnostics laboratories will further expand the market.

Restraints/Challenges Global Lung Cancer Diagnostics Market

On the other hand, huge cost associated with diagnostic imaging system is expected to obstruct market growth. Also, development of different diagnostic approaches for various cancer mutations is projected to challenge the lung cancer diagnostics market in the forecast period of 2022-2029.

This lung cancer diagnostics market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lung cancer diagnostics market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Lung Cancer Diagnostics Market

COVID-19 had a negative impact on the lung cancer diagnostics market owing to the supply chain disruptions and COVID-19 restrictions imposed by government. The manufacturing sector was hardly hit by the pandemic that declined the growth of the market. The implementation of global lockdown impacted the production schedules of the manufacturing industries. The sales dropped down amid the lockdown that resulted in drop in sales ratio and limited deliveries. However, market will resume its growth in the post-pandemic due to the easing in restrictions that were imposed earlier.

Recent Developments

  • Roche launched its Cobas Pulse System in selected countries accepting the CE Mark in January’2021. The product is Roche Diagnostics’ newest generation of connected point-of-care solutions. The new launch offers professional blood glucose management.

Global Lung Cancer Diagnostics Market Scope and Market Size

The lung cancer diagnostics market is segmented on the basis of test type, indication and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Test Type

  • CA Test
  • HER2 Tests
  • Alk Tests
  • Angiogenesis Inhibitor
  • Kras Mutation Tests
  • Others

On the basis of test type, the lung cancer diagnostics market is segmented into CA test, HER2 tests, ALK tests, angiogenesis inhibitor, KRAS mutation tests, and others.

Indication

  • Non Small-Cell Lung Cancer
  • Small-Cell Lung Cancer

On the basis of indication, the lung cancer diagnostics market is segmented into non small-cell lung cancer, and small-cell lung cancer.

End User

  • Hospital Associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others

On the basis of end user, the lung cancer diagnostics market is segmented into hospital associated labs, independent diagnostic laboratories, cancer research institutes, and others.

Lung Cancer Diagnostics Market Regional Analysis/Insights

The lung cancer diagnostics market is analysed and market size insights and trends are provided by country, test type, indication and end user as referenced above.

The countries covered in the lung cancer diagnostics market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the lung cancer diagnostics market because of the rise in incidence of lung cancer and growing aging population within the region.

Asia-Pacific (APAC) is expected to witness significant growth during the forecast period of 2022 to 2029 due to the increased use of lung cancer diagnostics due to rising tobacco smoking in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The lung cancer diagnostics market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for lung cancer diagnostics market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the lung cancer diagnostics market. The data is available for historic period 2010-2020.

Competitive Landscape and Lung Cancer Diagnostics Market Share Analysis

The lung cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lung cancer diagnostics market.

Some of the major players operating in the lung cancer diagnostics market are

  • H-Hoffman La-Rcohe Ltd. (Switzerland)
  • ABBOTT (US)
  • Danaher (US)
  • BD (US)
  • Thermo Fisher Scientific Inc. (US)
  • ACON Laboratories Inc. (US)
  • Hemosure, Inc. (US)
  • MicroGen Diagnostics (US)
  • QIAGEN (Germany)
  • Grifols, S.A (Spain)
  • BODITECH MED INC. (South Korea)
  • Chembio Diagnostic Systems, Inc. (US)
  • Nanoentek (South Korea)
  • DiaSorin S.p.A. (Italy)
  • Bio-Rad Laboratories, Inc. (US)
  • BIOMEDOMICS INC (US)
  • EKF Diagnostics Holdings plc (UK)
  • Siemens Healthcare GmbH (Germany)
  • PerkinElmer Inc. (US)
  • bioMérieux SA (France)
  • ARKRAY USA, Inc. (US)
  • Biohit Oyj (Finland)
  • Germaine Laboratories, Inc. (US)
  • Quidel Corporation (US)
  • Illumina, Inc. (US)
  • Lamdagen Corporation (US)
  • LifeSign LLC. (US)
  • Medixbiochemica (Finaland)
  • Nova Biomedical (US)
  • Ortho Clinical Diagnostics (US)
  • Sannuo Biosensing Co., Ltd. (US)
  • STRECK (US)
  • Sysmex Corporation (Japan)

Research Methodology : Global Lung Cancer Diagnostics Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available : Global Lung Cancer Diagnostics Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions

The Lung Cancer Diagnostics Market is expected USD 331,456.49 million by 2029.
The Lung Cancer Diagnostics Market is Expected to Witness CAGR of 7.80% During the Forecast Period of 2022 to 2029.
The Major Players Operating in the Lung Cancer Diagnostics Market are H-Hoffman La-Rcohe Ltd. (Switzerland), ABBOTT (US), Danaher (US), BD (US), Thermo Fisher Scientific Inc. (US), ACON Laboratories Inc. (US), Hemosure, Inc. (US), MicroGen Diagnostics (US), QIAGEN (Germany), Grifols, S.A (Spain), BODITECH MED INC. (South Korea), Chembio Diagnostic Systems, Inc. (US), Nanoentek (South Korea), DiaSorin S.p.A. (Italy), Bio-Rad Laboratories, Inc. (US), BIOMEDOMICS INC (US), EKF Diagnostics Holdings plc (UK), Siemens Healthcare GmbH (Germany), PerkinElmer Inc. (US), among others.
The Countries Covered in the Lung Cancer Diagnostics Market Report U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Russia, Turkey, Belgium, Netherlands, Switzerland, and Rest of Europe, Japan, China, South Korea, India, Australia & New Zealand, Singapore, Malaysia, Thailand, Indonesia, Philippines, and Rest of Asia-Pacific, Brazil, Argentina, and Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, and Rest of Middle East and Africa (MEA).
The Lung Cancer Diagnostics Market Report Curated by the Data Bridge Market Research Team Includes In-Depth Expert Analysis, Patient Epidemiology, Pipeline Analysis, Pricing Analysis, and Regulatory Framework.